By Julian Pecquet - 01/12/12 06:41 PM EST
The FDA struck a preliminary agreement with drugmakers in May over the prescription drug fee reauthorization, which is expected to sail through Congress. The deal calls for a $100 million increase in fees to pay for more than 100 extra staff members, two more meetings with sponsors during the drug review process and a two-month extension of the review time for new drugs.
The medical device fee is shaping up to be a tougher sell. Device makers want a revamp of the expedited approval process for low-risk devices, but patient advocacy groups say the current system is already too lax and allows dangerous products to get to market with little to no oversight.